A Mobile Supportive Care App for Patients With Metastatic Lung Cancer (LuCApp)
Nonsmall Cell Lung Cancer, Small Cell Lung Carcinoma
About this trial
This is an interventional supportive care trial for Nonsmall Cell Lung Cancer focused on measuring Lung Cancer
Eligibility Criteria
Inclusion Criteria:
- over 18 years of age individuals of both sexes;
- diagnosed with small or non-small cell lung cancer;
- patients eligible for chemotherapy, immunotherapy or biological therapy;
- patients diagnosed with non-resectable tumor and eligible for neoadjuvant therapies;
- life expectancy of six months or more;
- a performance status between 0 (asymptomatic) and 2 (symptomatic, <50% in bed during the day) according to the Eastern Cooperative Oncology Group (ECOG) score;
- patients fluently speaking Italian;
- patients able to provide informed consent to participate in the study;
- patients who own a smartphone that can access either the iOS or the Android platform.
Exclusion Criteria:
- individuals unable to provide written informed consent;
- individuals unable to see the App and all other materials (i.e. are blind);
- patients receiving or that plan to receive radiotherapy or surgical resection;
- patients already included or about to join other clinical trials;
- patients already using other smartphone applications to self-manage cancer symptoms.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
LuCApp + Standard Care
Standard Care
LuCApp (Lung Cancer App) is an application developed by researchers and lung cancer clinicians to gather symptom data in real time and to share it with healthcare professionals. LuCApp allows daily monitoring and grading of a list of symptoms which trigger alerts to the physicians in case predefined severity thresholds are met.
Usual care will consist of standard procedures currently available at participating centers for monitoring and documenting symptoms. These therapeutical procedures are based on the guidelines developed by the National Comprehensive Cancer Network (NCCN) and the Associazione Italiana di Oncologia Medica (AIOM). Symptoms for control arm patients will be discussed and registered during scheduled clinical visits with the oncologists. Standard-of-care patients will fill out their PROMs following the same schedule identified for LuCApp patients with paper questionnaires during clinic visits, or at home (having received paper questionnaires during the previous visit) or via telephonic interviews with the research team.